Moderna lays off 10% of workforce amid restructuring
- Moderna announced a plan to reduce its global workforce by 10%, expected to result in fewer than 5,000 employees by the end of 2025.
- The cuts are part of an effort to reduce operating expenses by approximately $1.5 billion by 2027.
- This decision reflects a need to reshape the operating structure and realign with business realities while continuing to invest in scientific research.
On July 31, 2025, biotechnology company Moderna announced a significant reduction in its workforce, planning to cut about 10% of its global team. This move comes as part of an effort to realign the company's cost structure and reduce operating expenses by approximately $1.5 billion by 2027. The CEO of Moderna, Stephane Bancel, communicated this decision in a memo, expressing the company's gratitude towards employees who have contributed to its mission. The anticipated job cuts are expected to reduce the workforce to fewer than 5,000 employees by the end of 2025. The decision to shrink the workforce does not appear to have been made lightly, according to Bancel's memo. He emphasized the impact on employees who have dedicated their time and efforts to the company and its mission. The restructuring reflects a broader trend in the biotechnology sector, where companies adjust to evolving market conditions and the necessity for financial discipline. In recent developments, Moderna received approval from the Food and Drug Administration for its next-generation COVID-19 vaccine. The company currently has three approved products and aims for eight more within the next year. Such advancements illustrate Moderna's commitment to scientific innovation amidst the background of organizational changes. While reshaping its operational structure, Moderna aims to maintain its focus on critical areas like oncology, rare diseases, and latent viruses. Bancel's remarks convey an intention to sharpen the company's focus and ambition, signifying that even amidst layoffs, the company aims to continue its investment in science. This move indicates both a reaction to market pressures and a commitment to sustain its scientific mission for future growth.